Document is current
Any future updates will be listed below
-
Authors
Brandl, Sarah
Yu, Qian
Hagenbuchner, Judith
Endmayr, Verena
Höftberger, Romana
Bradl, Monika
Reindl, Markus
-
Funding
Funding for this research was provided by:
Medical University of Innsbruck Ph.D. Research Training Groups (Project 2022-1-2 “CONNECT”)
Medical University of Innsbruck Ph.D. Research Training Groups (Project 2022-1-2 “CONNECT”)
Medical University of Innsbruck Ph.D. Research Training Groups (Project 2022-1-2 “CONNECT”)
China Scholarship Council (CSC 202306170046)
Austrian Research Promotion Agency (FO999920011)
Austrian Research Promotion Agency (FO999920011)
Austrian Science Fund (FWF grant 10.55776/PAT6054424)
Roche Austria GmbH (Restricted research grant)
- License Information
-
More Information
Article History
Received: 7 July 2025
Accepted: 3 November 2025
First Online: 8 December 2025
Ethics approval and consent to participate
: Serum samples from six NMOSD patients and neuropathological tissue sections from two NMOSD patients were provided by the biobank of the Department of Neuropathology, Medical University of Vienna, Austria. The use of these samples from a biobank for research studies was approved by the ethical committee of the Medical University of Vienna (EK 1636/2019 and 1123/2015). All patients or their legal representatives gave written informed consent to participate in the study and all methods were performed in accordance with the relevant guidelines and regulation.
: The authors declare that this study received funding from Roche Austria GmbH (to MR). The funder was not involved in the study design, analysis, or critical revision of the article for important intellectual content. RH reports speaker honoraria from UCB and BMS. The Medical Universities of Innsbruck (Austria; employer of MR) and Vienna (Austria; employer of RH) receive payments for antibody assays and for antibody validation experiments organized by Euroimmun (Lübeck, Germany). SB, QY, JH, VE and MB declare no competing interests.
